Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Gains from Investment Securities (2019 - 2024)

Vivos Therapeutics (VVOS) has disclosed Gains from Investment Securities for 6 consecutive years, with $5000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Investment Securities fell 94.19% to $5000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $111000.0, a 92.19% decrease, with the full-year FY2024 number at $1.2 million, up 874.8% from a year prior.
  • Gains from Investment Securities was $5000.0 for Q4 2024 at Vivos Therapeutics, down from $105000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.2 million in Q2 2022 to a low of -$157000.0 in Q3 2023.
  • A 5-year average of $823350.0 and a median of $295666.5 in 2020 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 1166.38% in 2022, then plummeted 257.0% in 2023.
  • Vivos Therapeutics' Gains from Investment Securities stood at $2.3 million in 2020, then plummeted by 95.05% to $114000.0 in 2021, then skyrocketed by 127.19% to $259000.0 in 2022, then plummeted by 66.8% to $86000.0 in 2023, then crashed by 94.19% to $5000.0 in 2024.
  • Per Business Quant, the three most recent readings for VVOS's Gains from Investment Securities are $5000.0 (Q4 2024), $105000.0 (Q3 2024), and $14000.0 (Q2 2024).